Earnings season kicks off this week, with at least 14 profitable biotechs and pharmas reporting financial results for 1Q10. Both Gilead Sciences Inc. (NASDAQ:GILD) and Novartis AG (NYSE:NVS; SIX:NOVN) are projected to report more than 40% increases in EPS. Gilead's revenues are expected to be $2.1 billion, up